Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Tufts University
Headquarters:
Medford, MA, United States
Website:
http://www.tufts.edu
Year Founded:
1852
Status:
Non-biopharma
Biopharma related deals can be found by searching the organization's name in the
Deals
Module.
BioCentury
|
Apr 11, 2025
Discovery & Translation
Base editor efficiency boom. China leading charge?
Recently published studies reveal advances in precision and performance, driven largely by labs in China
Read More
BioCentury
|
Jan 4, 2025
Market Access
Accelerated approval speed bump will limit access, disincentivize orphan drug development
Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months
Read More
BioCentury
|
Dec 6, 2024
Product Development
KCC2 activation nears inflection point
Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
Read More
BioCentury
|
Oct 8, 2024
Management Tracks
Veteran investor Oleg Nodelman joins Galapagos board
Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more
Read More
BioCentury
|
Jul 5, 2024
Product Development
LNP innovation: tissue specificity, aided by AI
How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
Read More
BioCentury
|
Jun 7, 2023
Finance
June 7 Quick Takes: Radiopharma play ITM raises €255M
Plus: LNP company Hopewell emerges with $25M seed round and updates from Mozart, GSK, FibroGen and Deerfield
Read More
BioCentury
|
Feb 15, 2023
Politics, Policy & Law
CMS proposes payment models for accelerated approval, gene & cell therapies
Models will not be implemented for years, industry will have chance to comment
Read More
BioCentury
|
Nov 8, 2022
Distillery Therapeutics
Lymph node-targeting lipid nanoparticle platform for mRNA vaccines
Read More
BioCentury
|
Jun 8, 2022
Regulation
FDA panel backs Novavax vaccine, citing need for another technology
Advisory committee says another non-mRNA vaccine is needed, expresses desire to encourage more COVID-19 vaccine development
Read More
BioCentury
|
May 12, 2022
Politics, Policy & Law
Biopharma companies facing tough decisions in Russia
Pharmaceutical companies balancing calls to disengage vs. duties to patients
Read More
Items per page:
10
1 - 10 of 130